{"result": "{\n    \"title\": \"Breast Cancer Research Community\",\n    \"summary\": \"The breast cancer research community revolves around a group of renowned researchers who have made significant contributions to the field of breast cancer treatment and diagnosis. The community is characterized by a network of relationships between these researchers, who have co-authored studies and developed clinical practice guidelines.\",\n    \"rating\": 8.0,\n    \"rating_explanation\": \"The impact severity rating is high due to the potential for breakthroughs in breast cancer treatment and diagnosis.\",\n    \"findings\": [\n        {\n            \"summary\": \"Key Researchers in the Community\",\n            \"explanation\": \"The breast cancer research community is led by a group of renowned researchers, including VIENS P, DAWOOD S, PALANGIE T, BEUZEBOC P, and DELOZIER T. These researchers have made significant contributions to the field, including the development of consensus statements and clinical practice guidelines. [Data: Entities (418, 416, 598, 603, 602); Relationships (342, 334, 338, 341, 340)]\"\n        },\n        {\n            \"summary\": \"Co-Authorship and Collaboration\",\n            \"explanation\": \"The researchers in the community have collaborated on numerous studies, with many co-authoring multiple papers. This level of collaboration suggests a high degree of trust and respect among the researchers, as well as a commitment to advancing the field of breast cancer research. [Data: Relationships (342, 334, 338, 341, 340)]\"\n        },\n        {\n            \"summary\": \"Clinical Practice Guidelines\",\n            \"explanation\": \"The community has developed clinical practice guidelines for early breast cancer diagnosis, treatment, and follow-up. These guidelines are a testament to the community's commitment to improving patient outcomes and advancing the field of breast cancer research. [Data: Relationships (447, 512, 445, 446, 448)]\"\n        },\n        {\n            \"summary\": \"Impact on Breast Cancer Research\",\n            \"explanation\": \"The breast cancer research community has the potential to make a significant impact on the field of breast cancer research. The development of new treatments and diagnostic tools could lead to improved patient outcomes and a better understanding of the disease. [Data: Entities (418, 416, 598, 603, 602); Relationships (342, 334, 338, 341, 340)]\"\n        },\n        {\n            \"summary\": \"Future Directions\",\n            \"explanation\": \"The breast cancer research community is poised for future growth and development. The continued collaboration and co-authorship among researchers will likely lead to new breakthroughs and advancements in the field. [Data: Entities (418, 416, 598, 603, 602); Relationships (342, 334, 338, 341, 340)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n418,\"\"\"VIENS P\"\"\",\"Here is a comprehensive summary of the data:\n\nVIENS P is a renowned researcher who has made significant contributions to the field of breast cancer treatment. Specifically, VIENS P was an author of several studies on breast cancer treatment, including a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, VIENS P conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining pathologic response and outcome. VIENS P's work has shed light on the diagnosis and treatment of inflammatory breast cancer, a rare and aggressive form of breast cancer.\",7\r\n416,\"\"\"DAWOOD S\"\"\",\"Here is a comprehensive summary of the data:\n\nDawood S is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, Dawood S is an author of multiple studies on the topic, including a study on the standardized diagnosis and treatment of inflammatory breast cancer, as well as a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer. These studies demonstrate Dawood S's expertise and research focus on inflammatory breast cancer, and highlight their role as a leading authority in the field.\",4\r\n598,\"\"\"PALANGIE T\"\"\",\"Here is a comprehensive summary of the data:\n\nPalangie T is an author of multiple studies related to inflammatory breast cancer. Specifically, Palangie T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.\",4\r\n603,\"\"\"BEUZEBOC P\"\"\",\"Here is a comprehensive summary of the data:\n\nBeuzeboc P is an author who has contributed to multiple studies in the field of breast cancer. Specifically, they have authored a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer. Additionally, they have also authored a study on inflammatory breast cancer, highlighting their expertise and research focus in this area.\",2\r\n602,\"\"\"DELOZIER T\"\"\",\"Here is a comprehensive summary of the data:\n\nDelozier T is an author of multiple studies related to inflammatory breast cancer. Specifically, Delozier T has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as a broader study on inflammatory breast cancer.\",2\r\n505,\"\"\"PENAULT-LLORCA F\"\"\",\"Here is a comprehensive summary of the data:\n\nPenault-Llorca F is a researcher who has made significant contributions to the field of early breast cancer diagnosis, treatment, and follow-up. Specifically, she has been involved in the development of ESMO Clinical Practice Guidelines for these areas. Additionally, she has authored a study on the use of high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer, examining the pathologic response and outcome of this treatment approach.\",2\r\n601,\"\"\"ROCHE H\"\"\",\"Here is a comprehensive summary of the data:\n\nRoche H is a researcher who has authored studies on inflammatory breast cancer. Specifically, Roche H has conducted research on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer, as well as on inflammatory breast cancer in general.\",2\r\n502,\"\"\"CARDOSO F\"\"\",\"\"\"Cardoso F is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",5\r\n503,\"\"\"KYRIAKIDES S\"\"\",\"\"\"Kyriakides S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",1\r\n504,\"\"\"OHNO S\"\"\",\"\"\"Ohno S is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",1\r\n506,\"\"\"POORTMANS P\"\"\",\"\"\"Poortmans P is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",1\r\n507,\"\"\"RUBIO IT\"\"\",\"\"\"Rubio IT is a researcher involved in the development of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",1\r\n634,\"\"\"BROGLIO K\"\"\",\"\"\"Broglio K is an author of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.\"\"\",1\r\n417,\"\"\"MERAJVER SD\"\"\",\"Here is a comprehensive summary of the data:\n\nMerajver SD is a notable figure in the field of inflammatory breast cancer research. As a contributor to the consensus statement for standardized diagnosis and treatment of inflammatory breast cancer, Merajver SD played a crucial role in shaping the understanding and management of this disease. Additionally, Merajver SD is also an author of a study on inflammatory breast cancer, further solidifying their expertise and contributions to the field.\",1\r\n419,\"\"\"VERMEULEN PB\"\"\",\"Here is a comprehensive summary of the data:\n\nVermeulen PB is a person who has made significant contributions to the field of inflammatory breast cancer. Specifically, they were a key contributor to the development of a consensus statement for standardized diagnosis and treatment of inflammatory breast cancer. Additionally, Vermeulen PB is also an author of a study on inflammatory breast cancer, further demonstrating their expertise and research in this area.\",1\r\n609,\"\"\"DIERAS V\"\"\",\"\"\"Dieras V is an author of a study on inflammatory breast cancer.\"\"\",1\r\n610,\"\"\"DORVAL T\"\"\",\"\"\"Dorval T is an author of a study on inflammatory breast cancer.\"\"\",1\r\n599,\"\"\"JANVIER M\"\"\",\"Here is a comprehensive summary of the data:\n\nJanvier M is an author of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: Since there is only one description provided, the summary is straightforward and concise.\",2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n342,\"\"\"VIENS P\"\"\",\"\"\"GONCALVES A\"\"\",\"\"\"Goncalves A and Viens P are co-authors of several studies on breast cancer treatment.\"\"\",14\r\n334,\"\"\"DAWOOD S\"\"\",\"\"\"VIENS P\"\"\",\"\"\"Dawood S and Viens P are co-authors of a study on inflammatory breast cancer.\"\"\",11\r\n338,\"\"\"VIENS P\"\"\",\"\"\"PALANGIE T\"\"\",\"Here is a comprehensive summary of the data:\n\nPalangie T and Viens P are co-authors of two studies related to inflammatory breast cancer. The first study focuses on inflammatory breast cancer, while the second study explores first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\n\nNote: The descriptions are identical, except for the order of the authors' names. This suggests that the two entities, Palangie T and Viens P, are co-authors of the same studies, and the descriptions are simply rephrased to reflect the different order of the authors' names.\",11\r\n341,\"\"\"VIENS P\"\"\",\"\"\"BEUZEBOC P\"\"\",\"\"\"Viens P and Beuzeboc P are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\"\"\",9\r\n340,\"\"\"VIENS P\"\"\",\"\"\"DELOZIER T\"\"\",\"\"\"Viens P and Delozier T are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\"\"\",9\r\n337,\"\"\"VIENS P\"\"\",\"\"\"PENAULT-LLORCA F\"\"\",\"\"\"Viens P and Penault-Llorca F are co-authors of a study on high-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome.\"\"\",9\r\n339,\"\"\"VIENS P\"\"\",\"\"\"ROCHE H\"\"\",\"\"\"Viens P and Roche H are co-authors of a study on first-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer.\"\"\",9\r\n447,\"\"\"CARDOSO F\"\"\",\"\"\"PENAULT-LLORCA F\"\"\",\"\"\"Cardoso F and Penault-Llorca F are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",7\r\n512,\"\"\"PALANGIE T\"\"\",\"\"\"BEUZEBOC P\"\"\",\"\"\"Palangie T and Beuzeboc P are co-authors of a study on inflammatory breast cancer.\"\"\",6\r\n445,\"\"\"CARDOSO F\"\"\",\"\"\"KYRIAKIDES S\"\"\",\"\"\"Cardoso F and Kyriakides S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",6\r\n446,\"\"\"CARDOSO F\"\"\",\"\"\"OHNO S\"\"\",\"\"\"Cardoso F and Ohno S are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",6\r\n448,\"\"\"CARDOSO F\"\"\",\"\"\"POORTMANS P\"\"\",\"\"\"Cardoso F and Poortmans P are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",6\r\n449,\"\"\"CARDOSO F\"\"\",\"\"\"RUBIO IT\"\"\",\"\"\"Cardoso F and Rubio IT are co-authors of ESMO Clinical Practice Guidelines for early breast cancer diagnosis, treatment, and follow-up.\"\"\",6\r\n336,\"\"\"DAWOOD S\"\"\",\"\"\"BROGLIO K\"\"\",\"\"\"Dawood S and Broglio K are co-authors of a study on the prognostic significance of HER-2 status in women with inflammatory breast cancer.\"\"\",5\r\n333,\"\"\"DAWOOD S\"\"\",\"\"\"MERAJVER SD\"\"\",\"\"\"Dawood S and Merajver SD are co-authors of a study on inflammatory breast cancer.\"\"\",5\r\n335,\"\"\"DAWOOD S\"\"\",\"\"\"VERMEULEN PB\"\"\",\"\"\"Dawood S and Vermeulen PB are co-authors of a study on inflammatory breast cancer.\"\"\",5\r\n513,\"\"\"PALANGIE T\"\"\",\"\"\"DIERAS V\"\"\",\"\"\"Palangie T and Dieras V are co-authors of a study on inflammatory breast cancer.\"\"\",5\r\n514,\"\"\"PALANGIE T\"\"\",\"\"\"DORVAL T\"\"\",\"\"\"Palangie T and Dorval T are co-authors of a study on inflammatory breast cancer.\"\"\",5\r\n516,\"\"\"JANVIER M\"\"\",\"\"\"DELOZIER T\"\"\",\"\"\"Janvier M and Delozier T are co-authors of a study on inflammatory breast cancer.\"\"\",4\r\n515,\"\"\"JANVIER M\"\"\",\"\"\"ROCHE H\"\"\",\"\"\"Janvier M and Roche H are co-authors of a study on inflammatory breast cancer.\"\"\",4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}